Bariatric surgery is one of the most studied interventions for severe obesity, yet many patients do not reach the weight-loss targets researchers consider optimal. That gap has prompted scientists to ask a straightforward question: does adding a peptide-based therapy on top of surgery produce better results than surgery alone?
A prospective, non-randomized controlled study published in the journal Obesity Surgery in 2026 set out to answer that question. Researchers enrolled patients with class II or class III obesity, meaning a body mass index of 35 or higher, who were already scheduled for laparoscopic sleeve gastrectomy. One group received the surgery plus a GLP-1 receptor agonist peptide (semaglutide) for the first six months after the procedure. The other group had surgery alone. Both groups were then followed for a full year.
The findings add a layer of hypothesis-generating evidence to a growing conversation about whether short-term peptide therapy and bariatric surgery can work together more effectively than either approach in isolation.
Study design and participants
The trial enrolled 103 participants in total. Forty-eight people were assigned to the treatment group, which received the GLP-1 peptide starting one month after surgery and continuing through month six. Fifty-five people formed the control group, which received surgery alone with no adjunctive peptide.
Because the study was non-randomized, participants were not randomly sorted into groups. Researchers acknowledged this limitation and used propensity score adjustment during analysis to account for differences in baseline characteristics between the two groups. The primary outcome the team set out to measure was the percentage of total weight lost, noted as percent total weight loss, at the twelve-month mark. Secondary outcomes included excess weight loss percentages and several metabolic indicators.
Exploratory analyses also looked at body composition, specifically lean body mass percentage and visceral fat area, though the investigators flagged those findings as preliminary and recommended cautious interpretation.
Weight loss results at twelve months
By the one-year follow-up, the group that received the adjunctive peptide showed meaningfully greater weight loss. Their average total weight loss reached 35.14 percent compared with 30.73 percent in the surgery-only group, a statistically significant difference with a p-value of 0.002.
The excess weight loss figure, which is a commonly used bariatric metric that measures how much of the weight above a target body mass index was shed, was also higher in the treatment group. The adjunctive peptide group averaged 86.42 percent excess weight loss versus 76.87 percent in the control group, reaching statistical significance at p equals 0.026.
The researchers also noted that the distribution of weight-loss outcomes, meaning the spread of individual results across participants, was more favorable in the treatment group. A larger proportion of peptide-group patients landed in higher weight-loss categories. After propensity score adjustment, the main total weight loss findings held up, though the difference in excess weight loss distribution between groups did not reach significance in that adjusted analysis.
Six-month interim measurements
The research team also measured outcomes at six months, which corresponds exactly to the end of the peptide treatment window. At that midpoint, total weight loss was again significantly greater in the treatment group, at 29.74 percent versus 26.32 percent in controls, with a p-value below 0.001.
Interestingly, the excess weight loss figure at six months did not show a statistically significant difference between the two groups at that timepoint. This pattern suggests the gap in excess weight loss may have widened or become more pronounced during the second half of the observation period, after the peptide course had already ended.
That trajectory raises questions the researchers themselves noted: could the early metabolic momentum established during the peptide treatment period have lasting effects? The study design cannot confirm causation, but the pattern is what the investigators describe as hypothesis-generating.
Metabolic indicators and body composition
Both the treatment and control groups showed comparable improvements in standard metabolic markers from their individual baselines. The abstract does not specify which metabolic parameters improved more in one group, suggesting the between-group differences in those measures were not the headline finding.
The exploratory body composition analyses are worth noting even with caveats. Researchers observed a greater increase in lean body mass percentage in the peptide group alongside a greater reduction in visceral fat area. Visceral fat, the fat stored around internal organs, is considered a marker of metabolic risk in the research literature. However, the investigators explicitly cautioned against over-interpreting these body composition results given the exploratory nature of the analysis and the non-randomized design.
How GLP-1 receptor agonists work
Semaglutide belongs to a class of peptides called GLP-1 receptor agonists. GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone released from the gut after eating. It signals to the brain that food has been consumed, slows the rate at which the stomach empties, and helps regulate blood glucose by stimulating insulin release in a glucose-dependent manner.
Synthetic GLP-1 receptor agonist peptides mimic and extend these signals. In a post-surgery context, the stomach has already been reduced in volume. The addition of a peptide that further slows gastric emptying and reinforces satiety signaling may compound the physiological changes already introduced by the procedure itself. The study does not propose a definitive mechanism, but the combined action of structural stomach reduction and hormonal appetite modulation is the framework researchers use to interpret the data.
It is also worth noting that sleeve gastrectomy itself has been shown to alter endogenous GLP-1 secretion in some research contexts, which makes the interaction between surgery and an external GLP-1 peptide a biologically plausible area for further investigation.
Limitations and what comes next
The researchers are candid about the constraints of their findings. This was a single-center, non-randomized study. Without randomization, unmeasured differences between the groups could influence results even after statistical adjustment. The sample size of 103 participants is relatively modest for drawing broad conclusions.
The study is best understood as preliminary, hypothesis-generating evidence rather than definitive proof that adjunctive peptide therapy should be added to post-surgical care. The investigators call for larger, randomized controlled trials to confirm or refute the association they observed.
For researchers and clinicians reviewing this work, the most relevant question it raises is whether the timing and duration of adjunctive peptide therapy after bariatric surgery can be optimized. The six-month treatment window chosen here was early and relatively brief. Whether longer courses, different starting points, or different peptide classes would produce different patterns remains an open research question that future trials will need to address.
